Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson's Disease Patients (PSYCHO-STIM).


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2020
Historique:
pubmed: 24 5 2020
medline: 16 9 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) negatively affects patients' Quality of Life (QoL) which depends on both objective criteria such as physical health and subjective ones such as worries and norms according to personal believes. Therefore, QoL could be also associated to personality dimensions in chronic neurological diseases such as PD. Our objective was thus to study the potential association between personality dimensions and QoL in PD patients with motor fluctuations before Deep Brain Stimulation of the Sub-Thalamic Nucleus (DBS-STN). Data were obtained from the French multicentric cohort study Predi-Stim. All PD patients awaiting DBS-STN and responding to the inclusion criteria at the time of the study were included. All participants answered the "Temperament and Character Inventory" (TCI) and the PDQ-39 before surgery. Analyses were made using adjusted univariate generalized linear regression models to evaluate a potential association between TCI dimensions and PDQ-39 scores. Three hundred thirty-three consecutive patients were included. The temperament Harm Avoidance was negatively associated with QoL (p = 1e-4, R2= 0.33), whereas the character Self-Directedness was positively associated with mental component of QoL (p = 2e-4, R2= 0.33) in PD patients with motor fluctuations awaiting DBS-STN. PD patients with motor fluctuations, with lower Harm Avoidance and higher Self-Directedness scores have the best QoL mainly at an emotional and social level. Therapeutic education of these PD patients focusing on their personal resources may thus be important to improve their well-being.

Sections du résumé

BACKGROUND
Parkinson's disease (PD) negatively affects patients' Quality of Life (QoL) which depends on both objective criteria such as physical health and subjective ones such as worries and norms according to personal believes. Therefore, QoL could be also associated to personality dimensions in chronic neurological diseases such as PD.
OBJECTIVE
Our objective was thus to study the potential association between personality dimensions and QoL in PD patients with motor fluctuations before Deep Brain Stimulation of the Sub-Thalamic Nucleus (DBS-STN).
METHODS
Data were obtained from the French multicentric cohort study Predi-Stim. All PD patients awaiting DBS-STN and responding to the inclusion criteria at the time of the study were included. All participants answered the "Temperament and Character Inventory" (TCI) and the PDQ-39 before surgery. Analyses were made using adjusted univariate generalized linear regression models to evaluate a potential association between TCI dimensions and PDQ-39 scores.
RESULTS
Three hundred thirty-three consecutive patients were included. The temperament Harm Avoidance was negatively associated with QoL (p = 1e-4, R2= 0.33), whereas the character Self-Directedness was positively associated with mental component of QoL (p = 2e-4, R2= 0.33) in PD patients with motor fluctuations awaiting DBS-STN.
CONCLUSIONS
PD patients with motor fluctuations, with lower Harm Avoidance and higher Self-Directedness scores have the best QoL mainly at an emotional and social level. Therapeutic education of these PD patients focusing on their personal resources may thus be important to improve their well-being.

Identifiants

pubmed: 32444557
pii: JPD191903
doi: 10.3233/JPD-191903
doi:

Banques de données

ClinicalTrials.gov
['NCT02360683']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1057-1066

Auteurs

Mathilde Boussac (M)

ToNIC, Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.

Christophe Arbus (C)

Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.

Julia Dupouy (J)

Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Estelle Harroch (E)

Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Vanessa Rousseau (V)

Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Fabienne Ory-Magne (F)

ToNIC, Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Olivier Rascol (O)

Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Caroline Moreau (C)

CHU of Lille, Univ. Lille, Inserm UMRS_1171, Licend, Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's Disease, Lille, France.

David Maltête (D)

Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.

Tiphaine Rouaud (T)

Clinique Neurologique, Hôpital Guillaume et René Laennec, Boulevard Jacques Monod, Nantes Cedex.

Mylène Meyer (M)

Neurology Department, Nancy University Hospital, Nancy, France.

Jean Francois Houvenaghel (JF)

Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes Cedex, France.

Claire Marsé (C)

CHU Nice, Centre Expert Parkinson, Service de Neurologie, Nice, France.

Christine Tranchant (C)

Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Elodie Hainque (E)

Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, Paris, France.

Béchir Jarraya (B)

Pôle Neurosciences, Foch Hospital, Suresnes, France; Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, Paris, France.

Solène Ansquer (S)

Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, Poitiers, France.

Marie Bonnet (M)

CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.

Lhaouas Belamri (L)

Hôpital Fondation A de Rothschild, service de recherche clinique, F-75019 Paris, France.

Mélissa Tir (M)

Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's Disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), Amiens, France.

Ana-Raquel Marques (AR)

Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France.

Teodor Danaila (T)

Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, Bron, France.

Alexandre Eusebio (A)

Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, Marseille, France.

David Devos (D)

CHU of Lille, Univ. Lille, Inserm UMRS_1171, Licend, Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's Disease, Lille, France.

Christine Brefel-Courbon (C)

ToNIC, Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH